Skip to Content
Merck

Key Documents

View All Documentation

L6292

Lisinopril

≥98% (HPLC), Angiotensin converting enzyme (ACE) inhibitor., solid

Synonym(s):

(S)-1-[N2-(1-carboxy-3-phenylpropyl)-lysyl-proline dihydrate, MK-521

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C21H31O5N3 · 2H2O
CAS Number:
83915-83-7
Molecular Weight:
441.52
UNSPSC Code:
12352200
PubChem Substance ID:
329817636
NACRES:
NA.32
MDL number:
MFCD01698825
Assay:
≥98% (HPLC)
Form:
solid
Quality level:
100
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Lisinopril, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

solid

color

white

solubility

H2O: ≥10 mg/mL, DMSO: ~6.5 mg/mL (with heating and sonicating)

storage temp.

2-8°C

SMILES string

[H]O[H].[H]O[H].NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N2CCC[C@H]2C(O)=O

InChI

1S/C21H31N3O5.2H2O/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15;;/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29);2*1H2/t16-,17-,18-;;/m0../s1

InChI key

CZRQXSDBMCMPNJ-ZUIPZQNBSA-N

Gene Information

human ... ACE(1636)

Application

Lisinopril has been used to study the antifibrotic effect in duchenne muscular dystrophy mice. It has been used to study the changes in renal-structure and -function in TGR(mRen2)27 (transgenic rat harboring the murine Ren-2 gene) rats upon long term darbepoetin α treatment.

Biochem/physiol Actions

Angiotensin converting enzyme (ACE) inhibitor.

Features and Benefits

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Still not finding the right product?

Explore all of our products under Lisinopril

pictograms

Health hazard
GHS08

signalword

Danger

Hazard Classifications

Repr. 1A - STOT RE 2

target_organs

Kidney

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000443941
0000443941
0000350813
0000350813
0000234768

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Anne-Roos S Frenay et al.
Journal of the renin-angiotensin-aldosterone system : JRAAS, 13(2), 232-238 (2012-01-28)
Erytropoietin (EPO) has cytoprotective and angiogenic properties and has a beneficial effect in ischaemic conditions. Since the development of renal interstitial abnormalities are often associated with ischaemia, we studied the effects of the long-acting EPO analogue darbepoetin alpha (DA) on
Tatjana Ignjatovic et al.
The Journal of biological chemistry, 277(19), 16847-16852 (2002-03-07)
Angiotensin I converting enzyme (kininase II; ACE) inhibitors are important therapeutic agents widely used for treatment in cardiovascular and renal diseases. They inhibit angiotensin II release and bradykinin inactivation; these actions do not explain completely the clinical benefits. We found
Nadir Ulu et al.
The Journal of pharmacology and experimental therapeutics, 345(3), 393-403 (2013-03-27)
Transactivation of epidermal growth factor receptor (EGFR) signaling by G protein-coupled receptors has been implicated in several cardiovascular (CV) conditions, including hypertension, heart failure, and cardiac and vascular hypertrophy. However, the therapeutic potential of EGFR inhibition in these conditions is
View All Related Papers